Citadel Advisors’s Traws Pharma TRAW Stock Holding History

Citadel Advisors’s Portfolio TRAW Stock Details TRAW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,264	Closed	-$121K	–	14924
2021 Q3	$121K	Buy	+1,264	New	+$163K	﹤0.01%	12639

Other funds holding TRAW

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $273M AUM

DIG

Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PWM

Palumbo Wealth Management Great Neck, New York $410M AUM 32.56% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Citadel Advisors's TRAW Position: Q1 2026 in Review

Citadel Advisors sold out of Traws Pharma (TRAW) in Q1 2026, closing a stake of 24,819 shares — an estimated $28K sold.

Citadel Advisors first reported a position in TRAW in Q4 2015 and held it in 20 quarters. The position peaked at $270K in Q3 2021. 28 funds tracked by Wall St. Rank hold TRAW as of Q1 2026.

Citadel Advisors reported no remaining Traws Pharma position as of Q1 2026 after selling out during the quarter.
Citadel Advisors sold 24,819 Traws Pharma shares in Q1 2026, an estimated $28K.
Citadel Advisors first reported a position in Traws Pharma in Q4 2015 and held it in 20 quarters.
Citadel Advisors's Traws Pharma position peaked at $270K in Q3 2021.
28 funds tracked by Wall St. Rank held Traws Pharma as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.